NIH/National Cancer Institute, Coordinated by ECOG-ACRIN Cancer Research Group
TMIST is first randomized, controlled trial that seeks to identify women in which digital breast tomosynthesis (DBT) may outperform 2D digital mammography in reducing advanced breast cancer development. The study will also create the world’s largest curated dataset of breast cancer screening clinical data, images and bio-specimens to help researcher’s tailor future screening to a woman’s individual risk.
University of Cincinnati Gardner Neuroscience Institute (UCGNI) – James J. & Joan A. Gardner Family Foundation (Alberto Espay, MD – Department of Neurology)
Theory is that neurodegenerative diseases such as Parkinson’s & Alzheimer’s are not one disease but many when considered from genetic and molecular perspectives. Study aimed at defining patient groups based on molecular features rather than symptoms to allow for early diagnosis and development of disease-specific neuroprotective treatment for each molecular form.
Cerevovus/Johnson & Johnson (Demchuk, Khatri, Nagel, Nogueira) 07/01/2018-06/01/2022
Primary objective to test efficacy and safety of immediate mechanical thrombectomy versus initial medical treatment in patients presenting with cerebral ischemia in the setting of proximal large vessel occlusions (LVO) and low baseline NIHSS score.
ClinicalTrials.gov Identifier: NCT04167527
Role: Imaging Management Center; Co-Central Reader: Achala Vagal, MD, MS
Primary objective to determine if acute ischemic stroke patients treated with IV rt-PA followed by argatroban or eptifibatide results in improved 90-day outcomes as compared with patients treated with IV rt-PA alone within 3 hours of symptom onset.
Specific aim of study to improve motor and cognitive recovery prediction after supratentorial intracerebral hemorrhage (ICH) by adding proportion of tract injury as measured by diffusion tensor imaging (DTI) independent of the ICH volume, location, age, gender and intraventricular hemorrhage (IVH). ClinicalTrials.gov Identifier: NCT04007757
Role: Imaging Core Lab; Co-investigator/Central Reader: Achala Vagal, MD, MS
Primary objective to test the hypothesis that treatment with rFIIa within two hours of symptom onset in appropriately selected patients with spontaneous intracerebral hemorrhage (ICH) improves outcome as measured by the ordinal distribution of the modified Rankin Scale (mRS) at 180 days as compared to placebo.
ClinicalTrials.gov Identifier: NCT03496883
Role: Imaging Management Center; Central Reader: Achala Vagal, MD, MS
Department of Radiology Pilot Grant (Verma) 06/2016-06/2018
Retrospective study to determine the diagnostic accuracy of MR textural analysis to differentiate benign transition zone prostatic hypertrophy from high-grade transition zone prostatic tumors by assessing transition zone heterogeneity.
NIH/NINDS RO1NS030678 (Kissela, Kleindorfer – Dept. of Neurology) 07/1993-04/01/2020
Major goals of project to examine incidence rates, causes, and treatment of ischemic and hemorrhagic stroke and to compare the incidence rate and survival of stroke and stroke sub-types in blacks and whites by gender and age group.
ClinicalTrials.gov Identifier: NCT00642213
Role: Co-Investigators: Thomas Tomsick, MD, Achala Vagal, MD, MS
Study to determine whether the addition of carotid endarterectomy to aggressive medical management can reduce the incidence of cerebral infarction in patients with asymptomatic carotid artery stenosis.
Role: Imaging Core Lab, Co-Investigator: Thomas Tomsick, MD
Primary goal to determine safety of the combination of medium dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide compared to standard dose rt-PA started within 3 hours of symptom onset in patients with acute ischemic stroke.
ClinicalTrials.gov Identifier: NCT00894803
Role: Imaging Core Lab, Co-Central Readers: Thomas Tomsick, MD, Achala Vagal, MD, MS
Primary goal to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.
ClinicalTrials.gov Identifier: NCT01977456
Role: Imaging Core Lab, Co-Central Readers: Thomas Tomsick, MD, Achala Vagal, MD, MS
Primary goal of study to evaluate the hypothesis that FDA cleared Thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or IC occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.
ClinicalTrials.gov Identifier: NCT02586415
Role: Local Site Principal Investigator: Achala Vagal, MD, MS
Major goal of this project to apply design thinking to understand the entire patient journey through radiology and create persona involving all stakeholders including patients, families, clinicians and radiology staff.
Randomized controlled study to test feasibility and provide preliminary data regarding the relative benefits and risks of combined intravenous and intra-arterial rt-PA for patients with acute ischemic stroke.
Primary goal of study to provide preliminary data about the benefits and risks of combined intravenous (IV) and intra-arterial (IA) rt-PA and low-intensity ultrasound energy in ischemic stroke patients with baseline NIHSS >/= 10 in whom IV treatment can be started within 3 hours of stroke onset..
ClinicalTrials.gov Identifier: NCT00243906
Role: Imaging Core Lab, Principal Interventional Investigator, Central CT & Angio Reader: Thomas Tomsick, MD
Goals of project to plan for submission of and possible execution of major multi-center phase III randomized trial of combined intravenous and intra-arterial approach to recanalization using rt-PA in patients with acute ischemic stroke.
Role: Co-Principal Investigator: Thomas Tomsick, MD
Primary goal of study to examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA alone when initiated within 3 hours of acute ischemic stroke onset.
ClinicalTrials.gov Identifier: NCT00359424
Role: Imaging Management Center, Angiography Core Lab, Principal Interventional Investigator, Co-Angiography Reader: Thomas Tomsick, MD
Multi-center, open-labeled, single arm pilot study to investigate the feasibility and safety of a combined intravenous and intra-arterial approach to recanalization using rt-PA in patients with ischemic stroke.
Role: Imaging Core Lab, Co-Principal Investigator, Central CT & Angio Reader: Thomas Tomsick, MD
NIH/NINDS UCLA SPOTRIAS Grant P50NS44378 (Kidwell) 05/2004-5/2010
Multi-center, randomized, controlled, blinded outcome evaluator, phase IIb trial to investigate whether diffusion-perfusion MR imaging can identify patients who will benefit substantially from mechanical embolectomy with the Concentric MERCI™ Retriever device for the treatment of acute ischemic stroke up to 8 hours from symptom onset.
Role: Local Site Principal Investigator: Thomas Tomsick, MD
University of Cincinnati is participating clinical site hub in a network with goal to improve outcomes of patients with acute neurologic problems through innovative research focused on the emergent phase of patient care.
Role: Co-Investigator UC NETT Team: Achala Vagla, MD, MS
Center for Clinical and Translational Science and Training (CCTST) KL2 Research Award (Vagal) 07/01/2015-06/30/2016
The goal of the study is to understand the natural fate and prognostic value of the penumbra in untreated patients. KL2 provides mentored career development experience in clinical and translational research.
American Roentgen Ray Society Scholarship (Vagal) 07/01/2012-06/30/2014
The goal of the study is to understand the natural fate and prognostic value of the ischemic penumbra. The ARRS Scholarship is intended to support study in a field selected by the scholar that will enable the scholar to attain his/her professional career goal.
Center for Clinical and Translational Science and Training (CCTST) CT2 Research Award (Vagal)
The goal of the study is to understand the natural fate and prognostic value of the penumbra in untreated patients. As the institutional equivalent of the CTSA funded KL2 program, the CT2 provides mentored career development experience in clinical and translational research.